How have FHTX and IMUX total returns compared?

Over the past 5 years, FHTX delivered -31.87% and IMUX delivered -35.70% annualized total return. Past performance doesn't predict future results.

Foghorn Therapeutics Inc. (FHTX) vs Immunic, Inc. (IMUX)

A side-by-side comparison of Foghorn Therapeutics Inc. and Immunic, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

FHTX

Foghorn Therapeutics Inc.

$112M

$1.91HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT

IMUX

Immunic, Inc.

$111M

$8.14HealthcareDelayed quote: Oct 6, 2026, 10:04 AM EDT

Total return — FHTX vs IMUX

growth of $100 · dividends reinvested · last 6y

FHTX -89.0% (-30.7%/yr)IMUX -95.1% (-39.6%/yr)FHTX compounded faster over this window

FHTX IMUX

FHTX vs IMUX: by the numbers

•FHTX is the larger company ($112M vs $111M market cap).
•Both run net losses; IMUX's is the smaller (0.00% vs -175.78% net margin).

Metrics side by side

Valuation

Metric	FHTX	IMUX
P/S ratio	3.05	N/A
P/B ratio	N/A	0.87

Profitability

Metric	FHTX	IMUX
Gross margin	89.22%	0.00%
Operating margin	-265.64%	0.00%
Net margin	-175.78%	0.00%
ROE	N/A	-87.45%
ROIC	-44.81%	-92.16%

Growth (annualized)

Metric	FHTX	IMUX
Revenue CAGR (5Y)	105.83%	N/A
Total return CAGR (5Y)	-31.87%	-35.70%

Frequently asked

How have FHTX and IMUX total returns compared?: Over the past 5 years, FHTX delivered -31.87% and IMUX delivered -35.70% annualized total return. Past performance doesn't predict future results.

Go deeper

Full FHTX analysis Full IMUX analysis Interactive comparison tool

Dig into the metrics

Foghorn Therapeutics ROE Immunic ROE Foghorn Therapeutics operating margin Immunic operating margin Foghorn Therapeutics revenue growth Immunic revenue growth Foghorn Therapeutics free cash flow Immunic free cash flow

Foghorn Therapeutics & Immunic appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.